Alum Rattavut Teerakapibal uses his passion and wealth of technical knowledge for formulation and process development to improve HIV therapies

Chronic diseases account for $3.8 trillion in annual health care spending in the United States. Patients’ lives are interrupted with recurring medical attention and burden. Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS) is one such chronic disease that requires lifelong treatment. Globally, more than 1 million people are diagnosed each year with HIV. As recently as 1996, the average life expectancy of a patient with HIV was less than 40 years. But with advances in treatment, if diagnosed early, HIV-positive patients today can have the same life expectancy as their HIV-negative counterparts.

Rattavut Teerakapibal (PhD ’18), a graduate of the University of Wisconsin–Madison School of Pharmacy, is one of the many researchers worldwide who are working to improve HIV therapies. As an investigator at GlaxoSmithKline (GSK), he supports the company’s ViiV Healthcare portfolio on HIV treatments and prevention.

Read full article at: